Comparative Pharmacology
Head-to-head clinical analysis: CEFTRIAXONE IN PLASTIC CONTAINER versus CEPHALEXIN.
Head-to-head clinical analysis: CEFTRIAXONE IN PLASTIC CONTAINER versus CEPHALEXIN.
CEFTRIAXONE IN PLASTIC CONTAINER vs CEPHALEXIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ceftriaxone inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking, leading to cell lysis mediated by autolytic enzymes. It has broad-spectrum activity against gram-positive and gram-negative bacteria.
Cephalexin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and disrupting cell wall cross-linking, leading to cell lysis and death.
1-2 g intravenously or intramuscularly every 12-24 hours, maximum 4 g daily.
Oral: 250-1000 mg every 6 hours; maximum 4 g/day.
None Documented
None Documented
Clinical Note
moderateCephalexin + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Cephalexin."
Clinical Note
moderateCephalexin + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Cephalexin."
Clinical Note
moderateCephalexin + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Cephalexin."
Clinical Note
moderateCephalexin + Sulfisoxazole
5.8-8.7 hours in adults; prolonged in neonates (18-25 h), elderly, and renal impairment.
0.5-1.2 hours in normal renal function; prolonged to 5-30 hours in severe renal impairment (CrCl <10 mL/min)
Renal (33-67% as unchanged drug), biliary/fecal (24-44% as active drug and metabolites).
Renal: 80-90% unchanged by glomerular filtration and tubular secretion; biliary: <5%; fecal: <1%
Category C
Category A/B
Cephalosporin Antibiotic
Cephalosporin Antibiotic
"The metabolism of Sulfisoxazole can be decreased when combined with Cephalexin."